Related Experiment Video
Updated: Jun 4, 2026
Detecting Migration and Infiltration of Neutrophils in Mice
Published on: February 6, 2020
Increased myeloperoxidase plasma levels in rheumatoid arthritis
Raissa Maria Sampaio Neves Fernandes1, Neusa Pereira da Silva, Emília Inoue Sato
1Brazilian Society of Rheumatology, Piauí, Brazil.
Abstract:
High myeloperoxidase (MPO) serum levels have been shown in several inflammatory diseases, including rheumatoid arthritis (RA). However, the correlation between MPO levels and disease activity in RA patients is still controversial. The aim of the study was to determine MPO plasma levels in RA patients and to investigate potential correlations between MPO levels and disease activity and treatment. MPO plasma levels were measured by ELISA according the manufacturer's instructions. Disease activity was measured by DAS28 ESR and DAS28 CRP scores, and patients were classified into 4 groups: group 1 DAS28 < 2.6; group 2: 2.6 ≤ DAS28 ≤ 3.2; group 3: 3.2 < DAS28 ≤ 5.1 and group 4: DAS28 > 5.1. Rheumatoid factor (RF) was measured by latex agglutination test, and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected by ELISA with a commercial kit. Fifty-seven female RA patients (mean age: 46.02 ± 13.47 years, mean disease duration: 115.77 ± 99.44 months) and sixty gender- and age-paired healthy controls were included. Mean MPO plasma levels were significantly higher in patients than in controls (72.27 pM vs. 40.78 pM, P = 0.007). RF was found in 59.6% and anti-CCP in 80.7% of the RA patients. No significant difference in MPO levels was seen among the four RA disease activity groups. We did not find significant correlation between MPO levels and disease activity as measured by DAS28 score. In conclusion, we observed significantly higher MPO plasma levels in RA patients when compared to healthy controls. However, we did not find correlation between MPO plasma level and disease activity.
Insights
Myeloperoxidase (MPO) plasma levels are elevated in rheumatoid arthritis (RA) patients compared to healthy individuals. However, MPO levels did not correlate with disease activity scores in RA patients.
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- High myeloperoxidase (MPO) serum levels are observed in various inflammatory conditions, including rheumatoid arthritis (RA).
- The relationship between MPO levels and RA disease activity remains a subject of debate.
- Understanding this correlation is crucial for assessing disease progression and treatment efficacy.
Purpose of the Study:
- To quantify MPO plasma levels in RA patients.
- To explore the association between MPO levels and disease activity measured by DAS28 scores.
- To investigate potential links between MPO levels and RA treatment.
Main Methods:
- MPO plasma levels were determined using ELISA.
- Disease activity was assessed using DAS28 ESR and DAS28 CRP scores, categorizing patients into four activity groups.
- Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies were measured.
Main Results:
- RA patients exhibited significantly higher MPO plasma levels (72.27 pM) compared to healthy controls (40.78 pM) (P=0.007).
- No significant differences in MPO levels were found across the four RA disease activity groups.
- A significant correlation between MPO plasma levels and DAS28 disease activity scores was not observed.
Conclusions:
- RA patients demonstrate elevated MPO plasma levels relative to healthy controls.
- MPO plasma levels do not appear to be directly correlated with disease activity in RA patients as assessed by DAS28 scores.
